Ehave Looks to Validate Medical Cannabis through “Right Data”


Ryan Allway

December 14th, 2017

Exclusive, News, Top News


The cannabis industry is projected to exceed $50 billion in the U.S. and $22.6 billion in Canada over the coming years, according to Cowen & Co. and Deloitte analysts, driven by the legalization of the drug across North America. Despite the widespread legalization, many physicians remain hesitant to prescribe the drug given the lack of “gold standard” clinical data surrounding its safety and efficacy in treating medical conditions.

Ehave Inc. (OTCQB: EHVVF) aims to change these dynamics by deploying its innovative mental health data platform into the medical cannabis industry. In partnership with a leading licensed producer, the company hopes to collect data to support a clinical trial of medical cannabis’ efficacy in treating post-traumatic stress disorder and other conditions.

Leading Mental Health Data Platform

Ehave has developed a mental health data platform designed for clinicians, patients, researchers, pharmaceutical companies, and payers. Through its two key components – MegaTeam and Ehave Connect – the platform is focused on leveraging the “right data” (rather than “big data”) to derive meaningful conclusions from vast data sets. This approach differentiates it from many other “big data” companies entering the space.

The MegaTeam component is a clinically validated digital assessment and rehabilitation software application designed to measure the cognitive abilities of patients with attention deficit hyperactivity disorder – or ADHD. The engaging video game-based environments include measurements like Stop Signal Reaction Time Assessment, N Back Assessment, Inhibitory Control Rehabilitation, and Working Memory Rehabilitation.

The Ehave Connect component is a cloud-based platform that enables the input, tracking, and extraction of clinical data while providing diagnosis and treatment insights to clinicians. Rather than relying on pen-and-paper assessments, the tool enables mental healthcare professionals to capture and record objective patient data through integrations with a community of third-party solutions, including licensed producers, assessments, diagnostics, and other devices.

Applications in Medical Cannabis

Ehave’s most recent focus has been in the medical cannabis industry, where its solutions are suitable for patients with PTSD, anxiety, traumatic brain injury, adult ADHD, depression, IBD, inflammation, CNS injury, and pain. Ehave Connect can be configured to capture and track the data required to evaluate cannabis-based therapeutics, from intake to assessment, treatment planning, delivery and adherence, to tracking of treatment outcomes.

On February 3, 2017, the company entered into an agreement with MedReleaf – a licensed producer under Health Canada’s ACMPR program – whereby the two companies agreed to develop a branded MedReleafApp utilizing the Ehave Connect platform to study the therapeutic use of medical cannabis. The initial focus is on the management of clinical trials to evaluate medical cannabis’ ability to relieve those suffering from PTSD. The digital intake patient platform launched in November and has experienced early success.

The long-term goal is to collect clinical data to create a data-rich network of patient information that has the potential to validate and legitimize the medical cannabis segment of the healthcare industry. Without “gold standard” assessments and clinical data, the industry has struggled to gain acceptance among mainstream doctors – even after the drug has been legalized throughout Canada and in many U.S. states.

Looking Ahead

Ehave Inc. (OTCQB: EHVVF) represents a compelling opportunity in the mental healthcare industry, particularly given its new focus on medical cannabis. Over the coming years, management plans to form strategic alliances with additional licensed producers of medical cannabis and publishers of psychological assessments, as well as cultivate relationships with pharmaceutical and insurance companies that could be instrumental in deploying its technology.

“As we ramp up our capabilities in artificial intelligence and machine learning, we begin to demonstrate the true capabilities of the Ehave platform,” said CEO Prateek Dwivedi in a recent press release. “Our platform goes beyond our best-in-class data management system to provide mental health practitioners with supplemental diagnosis data based on scoring results of multiple gold standard psychological assessments.”

For more information, visit the company’s website at www.ehave.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading